share_log

Jefferies Initiates Coverage On Ascendis Pharma With Buy Rating, Announces Price Target of $150

Benzinga ·  Dec 20, 2023 06:37

Jefferies analyst Kelly Shi initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Buy rating and announces Price Target of $150.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment